Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLG | P54098 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767234 | 1.00 | POLA1 (0.65) | POLA1PDE4DPDE3ASLC29A1POLB | |
| SCHEMBL12878118 | 1.00 | POLA1 (0.65) | POLA1PDE4DPDE3ASLC29A1POLB | |
| SCHEMBL12799369 | 1.00 | POLA1 (0.65) | POLA1PDE4DPDE3ASLC29A1POLB | |
| SCHEMBL12878128 | 0.92 | POLA1 (0.61) | POLA1PDE4DPDE3ASLC29A1POLB | |
| SCHEMBL12799372 | 0.92 | POLA1 (0.61) | POLA1PDE4DPDE3ASLC29A1POLB | |
| SCHEMBL12849778 | 0.92 | POLA1 (0.61) | POLA1PDE4DPDE3ASLC29A1POLB | |
| Psi-6130-Tp SCHEMBL15038016 | 0.91 | POLA1 (0.59) | POLA1PDE4DPDE3ASLC29A1POLB | |
| Psi-6130-Tp SCHEMBL12878130 | 0.91 | POLA1 (0.59) | POLA1PDE4DPDE3ASLC29A1POLB | |
| Psi-6130-Tp SCHEMBL465832 | 0.91 | POLA1 (0.59) | POLA1PDE4DPDE3ASLC29A1POLB | |
| Psi-6130-Tp SCHEMBL21233069 | 0.91 | POLA1 (0.59) | POLA1PDE4DPDE3ASLC29A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305060-A1 | Nucleoside Prodrugs and Uses Thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2009073506-A2 | NUCLEOSIDE PRODRUGS AND USES THEREOF | METABASIS THERAPEUTICS INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305060-A1 | Nucleoside Prodrugs and Uses Thereof | PNP, NUDT1, ENTPD5 | POLA1 1870/4885PDE4D 403/4885PDE3A 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.